FDA will take a flexible, albeit risk-based, approach on chemistry, manufacturing and controls data for products that are being developed or reviewed under an expedited regulatory program.
“Although sponsors must ensure the availability of quality product at the time of approval, FDA may exercise some flexibility on the type and extent of manufacturing information that is expected...